Indiana AG Hill announces multi-state settlement with Johnson & Johnson, subsidiary Ethicon Inc.

Court Money Settlement_-4812178250054614804

INDIANA (WEHT) – Indiana Attorney General Curtis Hill has announced a multi-state settlement with Johnson & Johnson and its subsidiary Ethicon Inc.

The settlement involves 41 states and the District of Columbia that would require Johnson & Johnson and its subsidiary Ethicon Inc. to pay nearly $116.9 million for their deceptive marketing of transvaginal surgical mesh devices.

A multi-state investigation found the companies violated state consumer protection laws by misrepresenting the safety and effectiveness of the devices and failing to disclose risks associated with their use.

Indiana will receive more than $4.4 million under the settlement.

Hill says his office will continue holding companies accountable “that cause harm to consumers through improper practices.”

Transvaginal surgical mesh is a synthetic material that’s surgically implanted through the vagina to support the pelvic organs of women who suffer from stress urinary incontinence or pelvic organ prolapse.

According to the settlement, the companies were aware of the possibility for serious medical complications but didn’t provide sufficient warnings to their consumers.

Among the specific requirements, the companies must:
• Refrain from referring to the mesh as “FDA approved” when that is not the case.
• Refrain from representing in promotions that risks associated with mesh can be eliminated with surgical experience or technique alone.
• Ensure that product training provided to medical professionals covers the risks associated with the mesh.
• Omit claims that surgical mesh stretches after implantation, that it remains soft after implantation, that foreign body reactions are transient and that foreign body reactions “may” occur (when in fact they will occur).
• Disclose that mesh risks include: fistula formation, inflammation, as well as mesh extrusion, exposure and erosion into the vagina and other organs.
• Disclose risks of tissue contraction, pain with intercourse, loss of sexual function, urge incontinence, de novo incontinence, infection following transvaginal implantation and vaginal scarring.
• Disclose that risks include that revision surgeries may be necessary to treat complications, that revision surgeries may not resolve complications and that revision surgeries are also associated with a risk of adverse reactions.

For the latest breaking news and stories from across the Tri-State, follow Eyewitness News on Facebook and Twitter.

(This story was originally published on October 17, 2019)

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories